Cargando…
Chemotherapy for ovarian cancer--a consensus statement on standard practice.
Autores principales: | Adams, M., A'Hern, R. P., Calvert, A. H., Carmichael, J., Clark, P. I., Coleman, R. E., Earl, H. M., Gallagher, C. J., Ganesan, T. S., Gore, M. E., Graham, J. D., Harper, P. G., Jayson, G. C., Kaye, S. B., Ledermann, J. A., Osborne, R. J., Perren, T. J., Poole, C. J., Radford, J. A., Rustin, G. J., Slevin, M. L., Smyth, J. F., Thomas, H., Wilkinson, P. M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063222/ https://www.ncbi.nlm.nih.gov/pubmed/9836470 |
Ejemplares similares
-
Targeted anti-vascular therapies for ovarian cancer: current evidence
por: Hall, M, et al.
Publicado: (2013) -
Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology Groups.
por: Gore, M. E., et al.
Publicado: (1997) -
Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.
por: Gore, M. E., et al.
Publicado: (1995) -
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
por: Ledermann, J.A., et al.
Publicado: (2021) -
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer
por: Harries, M, et al.
Publicado: (2004)